Answers are grounded in this paper and cite their sources.
Dengue is a vector-borne disease with a high health burden in tropical regions, yet no specific antiviral therapy is currently available. This study aimed to investigate the antioxidant activity, cytotoxicity, and antiviral activity against dengue virus serotype 2 (DENV-2) of the Niraga Tea PolyherbalTM formulation and performed phytochemical profiling and molecular docking. GC‒MS and FT‒IR analyses were used to analyze the profiles and structures of bioactive compounds; antioxidant activity was evaluated using the DPPH, ABTS, and FRAP methods; dengue antiviral activity was evaluated using the Viral ToxGlo assay; and cytotoxicity was evaluated using Vero cells in an MTT assay. Molecular docking evaluations of the compounds targeting the DENV-2 NS5 protein in silico. GC‒MS characterization revealed 100 compounds, predominantly methyl oleate (69.60%) and ethyl pentadecanoate (20.84%), along with quercetin (0.46%) and epigallocatechin gallate (0.19%). FT-IR analysis confirmed that phenolic hydroxyl groups were the dominant functional groups. DPPH, ABTS, and FRAP assays revealed IC50 values of 20.79, 21.34, and 18.80 µg/mL, respectively. MTT assays of Vero cells yielded a CC50 value of 1207 µg/mL. Niraga Tea PolyherbalTM significantly inhibited the cytopathic effects (F= 42.50; p=0.005), with an EC50 of 10.32 µg/mL and a selectivity index (SI) of 116.96 against DENV-2. Molecular binding studies of methyl oleate and ethyl pentadecanoate to DENV-2 NS5 revealed weak binding affinities (ΔG -3.95 to -4.31 kcal/mol), which were weaker than those observed with more potent in vitro compounds. In conclusion, Niraga Tea PolyherbalTM has the potential to be developed as a candidate phytopharmaceutical for dengue antiviral therapy with a high safety profile against host cells.
No takes yet. Share an insight, caveat, or question.
Rizqullah et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: